UnitedHealth’s Turnaround Rally Draws Wall Street’s Bullseye

UnitedHealth ( (UNH) ) has risen by 9.72%. Read on to learn why.

UnitedHealth shares climbed 9.72% over the past week as investors reacted to a string of upbeat analyst reports and stronger‑than‑expected first‑quarter results. The healthcare giant has rebounded sharply from its 2025 slump, with Wall Street now broadly viewing the stock as being in the early stages of a turnaround despite it still trading below last year’s levels. The latest move reflects growing confidence that the worst of the earnings pressure is behind the company.

Analysts highlight that UnitedHealth delivered a clear earnings beat, with first‑quarter EPS comfortably ahead of expectations and its key medical loss ratio coming in better than forecast, helped by disciplined pricing and controlled medical costs. Management also raised full‑year 2026 earnings guidance earlier than many had anticipated, reinforcing the view that underlying profitability is improving. While some, like BofA’s Kevin Fischbeck, remain cautious due to lingering uncertainty around Medicare Advantage rates, the tone across the Street has shifted notably more positive.

That optimism is showing up in price targets: Goldman Sachs, Morgan Stanley, Barclays and others have reiterated Buy ratings and raised or affirmed targets in the high‑$300s to $400 range, pointing to further potential upside from current levels. Analysts see long‑term growth drivers in UnitedHealth’s investments in AI, data‑driven care, and strategic portfolio moves such as acquisitions, divestitures and share buybacks. For investors, the recent 9.72% weekly gain signals renewed momentum in UnitedHealth’s stock as confidence builds around a multi‑year earnings recovery story.